The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The overall impact that the IRA will have on our business and the healthcare industry in general is not yet known.
All entries for: Psychiatry
March 16, 2026
Alto Neuroscience
Neutral Outlook
Mountain View, CA
51-200 employees
Since its enactment, there have been judicial, executive and political challenges and amendments to certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. It is unclear how other healthcare reform measures, if any, will impact our business.
Disease Area: Neurological Diseases, Psychiatry
Drug Type: Small Molecule
March 12, 2026
Tonix Pharmaceuticals Holding Corp.
Neutral Outlook
Berkeley, CA
51-200 employees
There is no assurance that federal or state health care reform will not adversely affect our future business and financial results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare policy will affect our business.
Disease Area: Immune Diseases, Infectious Diseases, Neurological Diseases, Oncology, Psychiatry, Rare Diseases
Drug Type: Biologic, Small Molecule
March 12, 2026
Lisata Therapeutics
Neutral Outlook
Basking Ridge, NJ
1-50 employees
Ultimately, the IRA’s impact on the biopharmaceutical industry in the United States remains uncertain, in part because of multiple ongoing lawsuits against CMS brought by large pharmaceutical companies and other stakeholders
Disease Area: Oncology, Psychiatry
Drug Type: Small Molecule
March 5, 2026
Contineum Therapeutics/CA
Negative Outlook
San Diego, CA
51-200 employees
The IRA and any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our future revenues and results of operations.
Disease Area: Immune Diseases, Neurological Diseases, Psychiatry, Respiratory Diseases
Drug Type: Small Molecule
March 4, 2026
GH Research PLC
Negative Outlook
Dublin, Ireland
1-50 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of our products and product candidates.
Disease Area: Psychiatry
Drug Type: Small Molecule
March 2, 2026
Supernus Pharmaceuticals
Neutral Outlook
Rockville, MD
501-1,000 employees
The Inflation Reduction Act of 2022 (IRA) includes measures intended to lower the cost of prescription drugs and related healthcare reforms, such as limits on price increases and subjecting an escalating number of drugs to annual price negotiations with Centers for Medicare & Medicaid Services (CMS). Specifically, the IRA authorizes and directs HHS to set drug price caps for certain high-cost Medicare Part B and Part D qualified drugs, with the initial list of drugs announced in August 2023.
Disease Area: Neurological Diseases, Psychiatry
Drug Type: Small Molecule